Literature DB >> 8478065

Reactivity of the human antiendotoxin immunoglobulin M monoclonal antibody HA-1A with lipopolysaccharides from rough and smooth gram-negative organisms.

M A Mascelli1, B Frederick, T Ely, D S Neblock, D J Shealy, K Y Pak, P E Daddona.   

Abstract

Clinical data suggest that the human immunoglobulin M antiendotoxin antibody HA-1A reduced mortality in patients diagnosed with gram-negative bacteremia and bacteremia with shock. Previous studies have demonstrated that HA-1A binds to the lipid A domain of lipopolysaccharide (LPS). The present study evaluated the ability of HA-1A to interact with LPs isolated from various strains of gram-negative bacteria by using liquid-phase rate nephelometry and solid-phase immunoblotting assays. HA-1A formed immune complexes in solution with LPSs isolated from both rough and smooth gram-negative organisms. Western blot (immunoblot) analysis of these LPS preparations revealed that HA-1A bound to LPS isolated from rough gram-negative organisms and to a rough LPS-like component present in smooth LPS. HA-1A also bound to LPS-protein complexes found in certain commercial rough LPS preparations. Preincubation of HA-1A with lipid A completely blocked subsequent binding of HA-1A to LPS in both liquid- and solid-phase assay formats, suggesting that the interaction of HA-1A with LPS is through the lipid A domain. Evidence that the binding of HA-1A to LPS was mediated through the antigen-combining (Fv) region of the antibody was provided by the finding that a murine anti-idiotypic antibody to HA-1A inhibited binding. These findings suggested that the broad antiendotoxin reactivity exhibited by HA-1A appeared to be due to the ability of HA-1A to bind to the conserved lipid A moiety of LPSs derived from both smooth- and rough-phenotype gram-negative bacterial strains.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478065      PMCID: PMC280762          DOI: 10.1128/iai.61.5.1756-1763.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

1.  Failure of monoclonal antibodies to core glycolipid to bind intact smooth strains of Escherichia coli.

Authors:  F Gigliotti; J L Shenep
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

Review 2.  Lipopolysaccharide nomenclature--past, present, and future.

Authors:  P J Hitchcock; L Leive; P H Mäkelä; E T Rietschel; W Strittmatter; D C Morrison
Journal:  J Bacteriol       Date:  1986-06       Impact factor: 3.490

3.  Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis.

Authors:  J L Shenep; K A Mogan
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

4.  The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.

Authors:  V L Tesh; R L Duncan; D C Morrison
Journal:  J Immunol       Date:  1986-08-15       Impact factor: 5.422

5.  Antibody-independent activation of the classical pathway of human serum complement by lipid A is restricted to re-chemotype lipopolysaccharide and purified lipid A.

Authors:  S W Vukajlovich
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

6.  Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity.

Authors:  W C Bogard; D L Dunn; K Abernethy; C Kilgarriff; P C Kung
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

7.  Immunologic activity of lipopolysaccharides released from macrophages after the uptake of intact E. coli in vitro.

Authors:  R L Duncan; J Hoffman; V L Tesh; D C Morrison
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

8.  Environmental modulation of lipopolysaccharide chain length alters the sensitivity of Escherichia coli to the neutrophil bactericidal/permeability-increasing protein.

Authors:  J Weiss; M Hutzler; L Kao
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

9.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.

Authors:  N N Teng; H S Kaplan; J M Hebert; C Moore; H Douglas; A Wunderlich; A I Braude
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

10.  Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5.

Authors:  R Sakulramrung; G J Domingue
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

View more
  2 in total

1.  Anti-lipid A monoclonal antibody centoxin (HA-1A) binds to a wide variety of hydrophobic ligands.

Authors:  E J Helmerhorst; J J Maaskant; B J Appelmelk
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

2.  alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.